Author: Lê, Minh Patrick; Le Hingrat, Quentin; Jaquet, Pierre; Wicky, Paul-Henri; Bunel, Vincent; Massias, Laurent; Visseaux, Benoit; Messika, Jonathan; Descamps, Diane; Mal, Hervé; Timsit, Jean-François; Peytavin, Gilles
Title: Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19 Cord-id: osccxxxn Document date: 2020_10_20
ID: osccxxxn
Snippet: Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo. Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir’s
Document: Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo. Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir’s metabolite (GS-441524) and sulfobutylether β-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19).
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low bioavailability: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lung transplant: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lung transplant patient: 1, 2
- acute respiratory syndrome cov and additional coinfection: 1, 2, 3
- acute respiratory syndrome cov and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute respiratory syndrome cov and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome cov and low bioavailability: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory syndrome cov and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome cov and lung transplant: 1, 2, 3, 4, 5, 6
- additional study and lopinavir ritonavir: 1, 2
- additional study and lung transplant: 1
- lopinavir ritonavir and low bioavailability: 1
- lopinavir ritonavir and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- lopinavir ritonavir and lung transplant: 1
- low molecular weight and lung transplant: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date